Search | Clinical Trials Finder

Conditions: Osteoporosis, Osteoporosis, Postmenopausal
Interventions: Parathyroid Hormone-related Protein, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Dengue
Interventions: ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC), Placebo; Drug · Other
Lead sponsor: Island Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: East Syracuse, New York

Conditions: Lung Cancer, Radiation Toxicity
Interventions: flaxseed, placebo; Dietary Supplement · Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 120 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Idaho Falls, Idaho • Indianapolis, Indiana

Conditions: Psoriatic Arthritis
Interventions: Deucravacitinib, Placebo, Apremilast; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 24
States / cities: Mountain Brook, Alabama • Sacramento, California • Whittier, California + 21 more

Conditions: Pre-Diabetes
Interventions: Vancomycin, Placebo, Neomycin, Clindamycin, Fecal Microbiota Transplantation; Drug · Other · Procedure
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypertension, Diabetes Type 2
Interventions: Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin, enalaprilat (ACE inhibitor), Glucagon-like peptide 1, brain natriuretic peptide; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Essential Tremor of the Upper Limbs
Interventions: IncobotulinumtoxinA, Placebo; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoporosis
Interventions: Teriparatide, Risedronate, Placebo, Calcium, Vitamin D; Drug · Dietary Supplement
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 6
States / cities: Fort Lauderdale, Florida • New Port Richey, Florida • Orlando, Florida + 3 more

Conditions: Diabetes Mellitus
Interventions: Exenatide, Exenatide matching placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 68
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 56 more

Conditions: Pneumococcal Infections
Interventions: V114, QIV, Matching Placebo for V114; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 45
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 39 more

Conditions: Bone Alteration, Dietary Modification
Interventions: Calcium/Vitamin D, Placebo; Dietary Supplement
Lead sponsor: United States Army Research Institute of Environmental Medicine; Federal
Eligibility: 17 Years to 42 Years
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Lassa Fever
Interventions: LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo, LASSARAB+ aPHAD-SEat 1400rU; Biological · Other
Lead sponsor: Wilbur Chen, MD, MS; Other
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections, Lipodystrophy
Interventions: Leptin, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 14 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Depressive Disorder, Major
Interventions: Omega 3 Fatty Acids, Corn oil; Drug · Dietary Supplement
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 12 Years to 19 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Peposertib, Placebo Administration; Procedure · Radiation · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 44
States / cities: Duarte, California • Irvine, California • Orange, California + 35 more

Conditions: Body Weight Changes
Interventions: Meal replacement shake, Multivitamin and mineral capsules, Fish oil with sesame lignans and olive extract softgel, Prebiotic Chewable tablet, Clove Extract and Maqui Berry extract capsule, .Whole Food Blend capsule, Turmeric extract capsule, European White Kidney Bean capsule, Saffron extract capsule, Ubiquinol with Fulvic acid complex softgel, Calcium with Hesperidin and gynostemma extract tablet, Multivitamin and mineral supplement; Dietary Supplement
Lead sponsor: Supplement Formulators, Inc.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Multiple Myeloma
Interventions: BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF; Drug
Lead sponsor: BioLineRx, Ltd.; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Gainesville, Florida • Miami, Florida + 7 more

Conditions: Pain, Peripheral Neuropathy, Neuropathic Pain
Interventions: Placebo, Tetrodotoxin; Drug
Lead sponsor: Wex Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 23
States / cities: Fountain Valley, California • Laguna Hills, California • Los Angeles, California + 18 more

Conditions: Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions: Fecal Microbiota Transplantation, Psyllium Husk Powder; Drug · Dietary Supplement
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriatic Arthritis
Interventions: Izokibep, Placebo to izokibep; Drug
Lead sponsor: ACELYRIN Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 40
States / cities: Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more

Conditions: Liver Disease, Short Bowel Syndrome
Interventions: Lovaza (omega-3-acid ethyl ester), Corn oil; Drug · Dietary Supplement
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 30 Days to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gingivitis
Interventions: Iocide Oral Rinse, Placebo; Drug
Lead sponsor: Biomedical Development Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Infant, Premature, Erythropoietin, Brain Injury, Intraventricular Hemorrhage, Periventricular Leukomalacia, Neurodevelopmental Outcomes, Randomized Clinical Trial
Interventions: Erythropoietin, Saline placebo; Drug
Lead sponsor: Atlantic Health System; Other
Eligibility: Up to 24 Hours
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Morristown, New Jersey

Search by objective public record fields.

3-Week Parathyroid Hormone-related Protein (PTHrP) Dose Escalation Study in Post-Menopausal Women

Study to Examine the Effects of Oral Fenretinide

Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy

Safety and Efficacy of Exenatide as Monotherapy

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

Interventional Bioremediation of Microbiota in Metabolic Syndrome

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

Botulinum Toxin A to Treat Arm Tremor

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Efficacy of a Once Daily Calcium and Vitamin D Fortified Food Product to Improve Bone Microarchitecture

DMID 23-0015; Lassa Fever CVD 1000

Therapeutic Approaches to HAART-Induced Lipodystrophy

The Role Of Omega-3 Fatty Acids In Adolescent Depression

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment

Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis

Psoriatic Arthritis Study of Izokibep

Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease

Dose-Response Study of Iocide Oral Rinse

High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study